Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 19, 2024 - Issue
Submit an article Journal homepage
140
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Biological Anti-IL-5/IL-5R Therapeutics for Chronic Obstructive Pulmonary Disease (COPD) with Specific Treatable Traits: A Real-World Retrospective Analysis

Forest Day de Larrañaga1 Research Institute of McGill University Health Centre, Montreal, Quebec, Canada;2 Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, CanadaORCID Iconhttps://orcid.org/0009-0002-9154-4400
ORCID Icon,
Alexandre Joubert3 COPD Clinic, McGill University Health Centre, Montreal, Quebec, Canada
,
Isabelle Drouin3 COPD Clinic, McGill University Health Centre, Montreal, Quebec, Canada
,
Isabelle Ouellet3 COPD Clinic, McGill University Health Centre, Montreal, Quebec, Canada
,
Pei Zhi Li1 Research Institute of McGill University Health Centre, Montreal, Quebec, Canada
,
Bryan A Ross1 Research Institute of McGill University Health Centre, Montreal, Quebec, Canada;2 Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada;3 COPD Clinic, McGill University Health Centre, Montreal, Quebec, Canada
,
Carolyn J Baglole1 Research Institute of McGill University Health Centre, Montreal, Quebec, Canada;2 Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, CanadaORCID Iconhttps://orcid.org/0000-0002-3107-0437
ORCID Icon &
Jean Bourbeau1 Research Institute of McGill University Health Centre, Montreal, Quebec, Canada;2 Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada;3 COPD Clinic, McGill University Health Centre, Montreal, Quebec, CanadaCorrespondence[email protected]
 show all
Pages 217-223 | Received 24 Oct 2023, Accepted 07 Jan 2024, Published online: 16 Jan 2024

References

  • Murray LA, Grainge C, Wark PA, Knight DA. Use of biologics to treat acute exacerbations and manage disease in asthma, COPD and IPF. Pharmacol Ther. 2017;169:1–12. doi:10.1016/j.pharmthera.2016.11.003
  • Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Clinical Trial, Phase II Randomized Controlled Trial Research Support, Non-U.S. Gov’t. Lancet Respir Med. 2021;9(11):1288–1298. doi:10.1016/S2213-2600(21)00167-3
  • Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
  • Agustí A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Am J Respir Crit Care Med. 2023;207(7):819–837. doi:10.1164/rccm.202301-0106PP
  • Narendra DK, Hanania NA. Targeting IL-5 in COPD. Int J COPD. 2019;14:1045–1051. doi:10.2147/COPD.S155306
  • Sciurba FC, Bradford ES, Pavord ID. Mepolizumab for Eosinophilic COPD. N Engl J Med. 2018;378(7):681–683. doi:10.1056/NEJMc1715454
  • Laroche J, Pelletier G, Boulay M, Côté A, Godbout K. Anti-IL5/IL5R Treatment in COPD: should We Target Oral Corticosteroid-Dependent Patients? Int J Chron Obstruct Pulmon Dis. 2023;18:755–763. doi:10.2147/copd.S370165
  • Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17(8):873–890. doi:10.1002/(sici)1097-0258(19980430)17:8<873::aid-sim779>3.0.co;2-i
  • Criner GJ, Celli BR, Brightling CE, et al. Benralizumab for the Prevention of COPD Exacerbations. Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t. N Engl J Med. 2019;381(11):1023–1034. doi:10.1056/NEJMoa1905248
  • Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. Clinical Trial, Phase IIIMulticenter Study Randomized Controlled Trial. N Engl J Med. 2017;377(17):1613–1629. doi:10.1056/NEJMoa1708208
  • Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med. 2023;389(3):205–214. doi:10.1056/NEJMoa2303951
  • Brightling CE, Bleecker ER, Panettieri RA, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Clinical Trial, Phase II Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t. Lancet Respir Med. 2014;2(11):891–901. doi:10.1016/S2213-2600(14)70187-0
  • Pavord ID, Chapman KR, Bafadhel M, et al. Mepolizumab for Eosinophil-Associated COPD: analysis of METREX and METREO. Int J COPD. 2021;16:1755–1770. doi:10.2147/COPD.S294333
  • Yousuf A, Ibrahim W, Greening NJ, Brightling CE. T2 Biologics for Chronic Obstructive Pulmonary Disease. Research Support, Non-U.S. Gov’t Review. j Allergy Clin Immunol Practice. 2019;7(5):1405–1416. doi:10.1016/j.jaip.2019.01.036

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.